Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:01 pm
Share
Singular Genomics Systems, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.462 million. Net loss was USD 22.36 million compared to USD 23.79 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.33 a year ago.
For the nine months, sales was USD 1.83 million. Net loss was USD 71.57 million compared to USD 69.78 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 0.98 a year ago.
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
SINGULAR GENOMICS SYSTEMS, INC. 
